Terms: = Kidney tumors AND LDH AND Prognosis
30 results:
1. Assessing the prognostic value of IMDC risk score for nivolumab-treated patients with renal cancer and malignant melanoma.
Beypınar I; Sözel Y; Önder AH
Cancer Biomark; 2023; 38(3):367-377. PubMed ID: 37718781
[TBL] [Abstract] [Full Text] [Related]
2. The novel role of ldhA/ldhB in the prognostic value and tumor-immune infiltration in clear cell renal cell carcinoma.
Chen J; Wu F; Cao Y; Xing Y; Liu Q; Zhao Z
PeerJ; 2023; 11():e15749. PubMed ID: 37547725
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic significance of 18F-FDG PET/CT indices in metastatic renal cell cancer and evaluation of revised IMDC risk model by including 18F-FDG PET-CT parameters.
Arikan R; Ozguven S; Telli TA; Isik S; Demircan NC; Basoglu T; Yasar A; Celebi A; Filizoglu N; Ustun HS; Tinay I; Ones T; Turoglu HT; Erdil TY; Ozturk MA; Ercelep O; Bayoglu V; Kostek O; Dane F; Yumuk PF
Acta Radiol; 2023 May; 64(5):2040-2049. PubMed ID: 36447438
[TBL] [Abstract] [Full Text] [Related]
4. Improved method to stratify lymphoma patients with risk of secondary central nervous system involvement: A multicenter retrospective analysis.
Lang M; Feng Y; Meng X; Zhao J; Song Z; Qian Z; Qiu L; Zhou S; Liu X; Li L; Yang H; Song Y; Li W; Zhang H
Hematol Oncol; 2023 Apr; 41(2):239-247. PubMed ID: 34564882
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic role of pretreatment lactate dehydrogenase in patients with metastatic renal cell carcinoma: A systematic review and meta-analysis.
Zhang N; Zhang H; Zhu D; JiRiGaLa ; Yu D; Wang C; WuYunBiLiGe ; Amin ; ZhiHong ; Yu H; Chen X; Wang M
Int J Surg; 2020 Jul; 79():66-73. PubMed ID: 32417461
[TBL] [Abstract] [Full Text] [Related]
6. Three gold indicators for breast cancer prognosis: a case-control study with ROC analysis for novel ratios related to CBC with (ALP and ldh).
Said NM
Mol Biol Rep; 2019 Apr; 46(2):2013-2027. PubMed ID: 30706358
[TBL] [Abstract] [Full Text] [Related]
7. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy.
El-Galaly TC; Villa D; Michaelsen TY; Hutchings M; Mikhaeel NG; Savage KJ; Sehn LH; Barrington S; Hansen JW; Smith D; Rady K; Mylam KJ; Larsen TS; Holmberg S; Juul MB; Cordua S; Clausen MR; Jensen KB; Johnsen HE; Seymour JF; Connors JM; de Nully Brown P; Bøgsted M; Cheah CY
Eur J Cancer; 2017 Apr; 75():195-203. PubMed ID: 28237865
[TBL] [Abstract] [Full Text] [Related]
8. [Analysis of Clinical Feature and Treatment Outcome of Patients with Renal Diffuse Large B Cell Lymphoma].
Yang P; Jing HM; Zhao W; Hu K; Wan W; Tian L; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1737-1742. PubMed ID: 28024486
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic Value of Serum Lactate Dehydrogenase in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Shen J; Chen Z; Zhuang Q; Fan M; Ding T; Lu H; He X
PLoS One; 2016; 11(11):e0166482. PubMed ID: 27861542
[TBL] [Abstract] [Full Text] [Related]
10. Opposite prognostic roles of HIF1α and HIF2α expressions in bone metastatic clear cell renal cell cancer.
Szendrői A; Szász AM; Kardos M; Tőkés AM; Idan R; Szűcs M; Kulka J; Nyirády P; Szendrői M; Szállási Z; Győrffy B; Tímár J
Oncotarget; 2016 Jul; 7(27):42086-42098. PubMed ID: 27244898
[TBL] [Abstract] [Full Text] [Related]
11. A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2.
Soerensen AV; Geertsen PF; Christensen IJ; Hermann GG; Jensen NV; Fode K; Petersen A; Sandin R; Donskov F
Acta Oncol; 2016; 55(3):341-8. PubMed ID: 26449266
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry.
Kubackova K; Bortlicek Z; Pavlik T; Melichar B; Linke Z; Pokorna P; Vyzula R; Prausova J; Buchler T;
Target Oncol; 2015 Sep; 10(3):385-92. PubMed ID: 25304882
[TBL] [Abstract] [Full Text] [Related]
13. Clinical prognostic factors associated with outcome in patients with renal cell cancer with prior tyrosine kinase inhibitors or immunotherapy treated with everolimus.
Amato RJ; Flaherty A; Zhang Y; Ouyang F; Mohlere V
Urol Oncol; 2014 Apr; 32(3):345-54. PubMed ID: 24321256
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic significance of basic laboratory methods in non- small-cell-lung cancer.
Kaya V; Yildirim M; Demirpence O; Yildiz M; Yalcin AY
Asian Pac J Cancer Prev; 2013; 14(9):5473-6. PubMed ID: 24175844
[TBL] [Abstract] [Full Text] [Related]
15. Improvement of prognosis in patients with metastatic renal cell carcinoma and Memorial Sloan-Kettering Cancer Center intermediate risk features by modern strategy including molecular-targeted therapy in clinical practice.
Kamba T; Yamasaki T; Teramukai S; Shibasaki N; Arakaki R; Sakamoto H; Matsui Y; Okubo K; Yoshimura K; Ogawa O
Int J Clin Oncol; 2014; 19(3):505-15. PubMed ID: 23813043
[TBL] [Abstract] [Full Text] [Related]
16. Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline.
Donat SM; Diaz M; Bishoff JT; Coleman JA; Dahm P; Derweesh IH; Herrell SD; Hilton S; Jonasch E; Lin DW; Reuter VE; Chang SS
J Urol; 2013 Aug; 190(2):407-16. PubMed ID: 23665399
[TBL] [Abstract] [Full Text] [Related]
17. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.
Armstrong AJ; George DJ; Halabi S
J Clin Oncol; 2012 Sep; 30(27):3402-7. PubMed ID: 22891270
[TBL] [Abstract] [Full Text] [Related]
18. Is Memorial Sloan-Kettering Cancer Center risk classification appropriate for Japanese patients with metastatic renal cell carcinoma in the cytokine era?
Shinohara N; Abe T; Mochizuki T; Kashiwagi A; Kanagawa K; Maruyama S; Sazawa A; Oba K; Nonomura K
Urol Oncol; 2013 Oct; 31(7):1276-82. PubMed ID: 21956045
[TBL] [Abstract] [Full Text] [Related]
19. Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation.
Peccatori J; Barkholt L; Demirer T; Sormani MP; Bruzzi P; Ciceri F; Zambelli A; Da Prada GA; Pedrazzoli P; Siena S; Massenkeil G; Martino R; Lenhoff S; Corradini P; Rosti G; Ringden O; Bregni M; Niederwieser D;
Cancer; 2005 Nov; 104(10):2099-103. PubMed ID: 16220555
[TBL] [Abstract] [Full Text] [Related]
20. [Clinical significance of erythrocyte sedimentation rate, C-reactive protein and serum lactate dehydrogenase levels in the diagnosis, prognosis and treatment monitoring of children suffering from cancer].
Bień E; Balcerska A
Med Wieku Rozwoj; 2004; 8(4 Pt 2):1081-9. PubMed ID: 15951603
[TBL] [Abstract] [Full Text] [Related]
[Next]
